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                 INTRODUCTION 
 
1. INTRODUCTION 
          Analytical chemistry may be defined as the science and art of determining the composition of 
material in terms of elements or compounds contained in it
1
. Analytical chemistry is divided into two 
branches quantitative and qualitative. A qualitative method is the information about the identity of 
atomic or molecular species or functional groups in the sample. A quantitative method provides 
numerical information as to the relative amount of one or more of these components. 
   For analysis of these drugs different analytical methods are routinely being used. These 
analytical methods are classified as chemical and instrumental.  The chemical methods include 
Gravimetric and Titrimetric. These methods are simple but less precise and more time consuming so 
now days these methods are not suggested for the routine analysis. The instrumental methods include 
electrochemical methods - Electro gravimetric method, Potentiometry, Colorimetry, Conductometry, 
Polarography and Optical methods - Absorption and Emission methods. The Absorption methods include 
Visible Spectrophotometry, Ultraviolet Spectrophotometry, Atomic Absorption Spectrophotometry, 
Infrared Spectrophotometry, and Emission methods include Emission Spectroscopy, Flame Photometry, 
Fluorimetry, etc. The other outstanding methods include isotopes, radioactivity, X-ray fluorescence and 
separation methods as various chromatographic principles viz. HPLC, GC, HPTLC, LC-MS
2
. 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC): 
HPLC is a fast growing analytical technique for the analysis of drugs. Its simplicity, specificity and 
wide range of sensitivity make it ideal for the analysis of many drugs in both dosage forms and biological 
fluids
3
. 
 The rate of distribution of drugs between stationary and mobile phase is controlled by diffusion 
process. If diffusion is minimized, a faster and effective separation can be achieved. The technique of 
high performance liquid chromatography is so called because of its improved performance when 
compared to conventional column chromatography. Advances in column technology, high pressure 
pumping system and sensitive detectors have transformed liquid column chromatography into high 
efficient, accurate and highly resolved method of separation
4
.
 
For the present study, the drug Atazanavir 
Sulphate and Ritonavir was selected for the estimation. 
The HPLC method was considered the choice of estimation, since this method is the most 
powerful of all chromatographic and other separative methods. The HPLC method has enabled 
analytical chemist to attain great success in solving his analytical problems. 
Method Development: 
The development of a method of analysis of any compound is usually based on existing 
literature, using same or quite similar instrumentation. But now days HPLC based method is not similar 
as compare to existing literature based approaches. The development of new or any improved method 
should be beneficial in any way than the existing method. Method development usually requires 
selecting the method requirement and deciding the instrumentation to utilize for what purpose
5
. 
Method development is done for, new drug products and already existing products. The various 
parameters that include to be optimized during method development are 
 Mode of separation. 
 Selection of stationary phase. 
 Selection of mobile phase. 
 Selection of detector  
Method validation:
 
Validation of an analytical method is the process by which it is established, by laboratory 
studies, that the performance characteristics of the method meet the requirements for the intended 
analytical applications. 
Validation is defined by different agencies. According to Food and Drug administration (FDA), 
validation is establishing documentation evidence, which provides a high degree of assurance that 
specific process will consistently produce a product meeting its predetermined specification and quality 
attributes. 
According to World Health Organization (WHO), validation is an action of providing that any 
procedure, process, equipment, material, activity, or system actually leads to the expected results
6
. 
Validation parameter includes accuracy, precision, system suitability, linearity, ruggedness, 
robustness, limit of detection and limit of quantitation. 
The principal purpose of analytical method validation is to ensure that test methods, which are 
used for assessing compliance of pharmaceutical products with established specifications, will give 
accurate, reliable and reproducible results. 
         The number of drugs and drug formulations introduced into the market has an alarming rate. 
These drugs or formulations may be either in the new entities in the market or partial structural 
modification of the existing drugs or novel dosage forms or multi component dosage forms. 
Applications: 
a. Chemistry and biochemistry research analyzing complex mixtures 
b. Developing processes for synthesizing chemical compounds 
c. Purifying chemical compounds 
d. Quality control to ensure the purity of raw materials, to control and improve process yields, to 
quantify assays of final products or to evaluate product stability and monitor degradation.  
e. Isolating natural products or predicting physical properties.  
The HPLC method was considered the choice of estimation, since this method is the most 
powerful of all chromatographic and other separative methods.  The HPLC method has enabled 
analytical chemist to attain great success in solving his analytical problems.  
Atazanavir sulphate is an antiretroviral drug of the protease inhibitor class, it is used to treat 
infection of human immunodeficiency virus Used in combination with other antiretroviral agents for the 
treatment of HIV-1 infection, as well as post exposure prophylaxis of HIV infection in individuals who 
have had occupational or no occupational exposure to potentially infectious body fluids of a person 
known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. 
Ritonavir an HIV protease inhibitor that works by interfering with the reproductive cycle of HIV is an 
antiretroviral drug of the protease inhibitor class, it is used to treat infection of human 
immunodeficiency virus. 
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    LITERATURE REVIEW 
 
2. LITERATURE REVIEW 
Normal-phase HPLC (NP-HPLC), or adsorption chromatography, this method separates 
analytes   based on their affinity for a polar stationary surface such as silica, hence it is based on 
analyte ability to engage in polar interactions (such as hydrogen-bonding or dipole-dipole type of 
interactions) with the sorbent surface. To select an optimum mobile phase it is better to start with 
pure hydro carbon mobile phase such as heptanes. In normal phase mode, separations of oil 
soluble vitamins, essential oils, can be done using binary mobile phase7.  
 
 
. 
              Solvent Pumping system 
 
 
          Shimadzu   LC 2010 HPLC 
 
                                                                                      UV detector 
 
 
 Reverse phase HPLC (RP-HPLC) has a non-polar stationary phase and an aqueous, 
moderately polar mobile phase. One common stationary phase is silica which has been surface-
modified with RMe2SiCl, where R is a straight chain alkyl group such as C18H37 or C8H17.With 
such stationary phases, retention time is longer for molecules which are less polar, while polar 
molecules elute more readily. Generally the lower the polarity of the mobile phase the higher is 
its elution strength. Thus water is the weaker solvent. Methanol and acetonitrile are popular 
solvents because of its low viscosity and are readily available with excellent purity. We have 
selected Atazanavir sulphate and Ritonavir for the present work and literature cited on the above 
drugs were listed below. 
A sensitive method for the simultaneous estimation of Ritonavir in their dosage form was 
developed and validated. The method was carried out on a Thermo Hypersil RP C-18 column 
(150 mm x 4.6 mm, 5 µm) with a mobile phase consisting of Acetonitrile: Potassium dihydrogen 
Phosphate & di potassium hydrogen Phosphate (45: 55 V/V) at a flow rate of 1 mL min-1 and the 
detection was carried out at 239 nm. The limits of detection (LOD) and quantification (LOQ) 
were 0.09 and 0.027 µg/ mL respectively. Precision % RSD values were found to be 0.38% and 
0.41% respectively. Recovery of Ritonavir was found to be in the range of 99.90-100.50%. The 
retention time of Ritonavir was 3.11 min respectively. Linearity for Ritonavir were found in the 
range of 20-120 µg/ mL-1 8.  
A reverse phase high performance liquid chromatographic method was developed and 
validated for the simultaneous estimation of Lopinavir and Ritonavir in Bulk and Tablet dosage 
form. A Hypersil (ODS) C8 (250 × 4.6mm, 5 µm) id in isocratic mode with mobile phase 
containing acetonitrile: methanol:                                0.01 M potassium dihydrogen 
orthophosphate buffer at pH 3.0 (30:20:50 V/V/V) was used. The flow rate was 1 mL min-1 and 
effluents were monitored at 254 nm. The retention time of Atazanavir Sulphate and Ritonavir 
was 4.66 min and 3.44 min respectively. The concentration curves were linear in the 
concentration range of 80–120 µg/ mL-1 for both the drugs. The developed method was validated 
for specificity, precision, linearity, accuracy, LOD, LOQ, robustness. Recovery of Lopinavir and 
Ritonavir in formulations was found to be in the range of 98% -102% respectively confirms the 
non-interferences of the excipients in the formulation9. 
 A high-performance liquid chromatographic method for the determination of atazanavir 
(ATV) in human plasma is developed and validated. The method involves a rapid and simple 
solid-phase extraction of ATV using Bond-elut C18 3 mL cartridge. The separation of ATV from 
internal standard and endogenous components is achieved using an isocratic elution on an octyl 
column and an UV detector set at 260 nm. The method is linear from 20 to 10,000 µg/ mL (mean 
r
2
 = 0.9991, n = 10). The observed intra- and inter-day assay precision ranged from 2.2% to 
14.7% at the lower limit of quantitation (LOQ), where as accuracy varies between 1.0% and 14% 
(at LOQ). Mean drug recovery is 80.5% for ATV and 78.4% for IS10. 
A new, simple, sensitive, precise and accurate High-performance thin-layer 
chromatographic method for simultaneous determination of Ritonavir and Atazanavir in their 
combined tablet dosage form has been developed, validated and used for determination of the 
compounds in commercial pharmaceutical products. Chromatographic separation was achieved 
on aluminium plates precoated with silica gel 60 F254 as the stationary phase and chloroform: 
ethyl acetate: acetone            (5:2:3 V/V/V) as a mobile phase. Densitometric measurements of 
their spots were achieved at 244 nm over the concentration ranges of 800-2800 µg spot-1 and 
2400-8400 µg spot-1, with mean recoveries of 98.57 ± 0.35 and 99.16 ± 0.20 for ritonavir and 
atazanavir respectively. Limit of detection for ritonavir and atazanavir were found to be 300 µg 
spot-1 and 200 µg spot-1 respectively. Chromatogram of standard Ritonavir Rf = 0.28 and 
Atazanavir Rf = 0.5811. 
Chemometrics-assisted spectrophotometry for the determination of two protease 
inhibitors, lopinavir and ritonavir, in plasma was evaluated. A set of calibration mixtures was 
designed according to central composite design. The UV spectra obtained from the calibration 
set were subjected to partial least square regression to construct the prediction models for 
lopinavir and ritonavir in unknown samples, which were then validated in a randomly selected 
set of synthetic mixtures of the drugs. An optimum model was obtained in the wavelength ranges 
of             215–249 nm and 240–279 nm with principal components 8 for both lopinavir and 
ritonavir respectively. The prediction models were used to analyse the two drugs in plasma and 
the results were compared with those obtained by high-performance liquid chromatography 
(HPLC). The PLS-1 model and the HPLC method were found to be comparable12. 
 A simple, precise, specific and accurate reverse phase HPLC method has been developed 
for the determination of Atazanavir and Ritonavir in pharmaceutical dosage forms. The 
chromatographic separation was achieved on Symmetry              C8 (4.6 x 100mm, 5 µm) 
column using a mixture of Buffer: Acetonitrile (45:55 V/V) as the mobile phase at a flow rate 0.9 
mL/ min. The retention time of Atazanavir and Ritonavir was 2.9 min and 4.1 min. The analyte 
was monitored using UV detector at 235 nm. Results of analysis were validated statistically and 
by recovery studies. The method was validated according to the ICH guidelines with respect to 
linearity, accuracy, precision and robustness. The proposed method can be successfully used to 
determine the drug contents of marketed formulation13. 
A simple, precise, accurate, and rapid HPLC method has been developed, and validated 
for the determination of Atazanavir and Ritonavir simultaneously in combined tablet dosage 
form. The mobile phase used was a mixture of phosphate buffer pH 4.0 and Acetonitrile (43:57 
V/V). The detection of Atazanavir and Ritonavir was carried out by UV detector at 240 nm. The 
retention time of Atazanavir and Ritonavir were found to be 4.2 min and 5.2 min respectively. 
Results of the analysis were validated statistically, and by recovery studies. The proposed 
method can be successfully used to determine the drug contents of marketed formulation14. 
Simple, precise, rapid and accurate methods for simultaneous determination of 
Atazanavir and Ritonavir in combined tablet dosage form have been developed. Method A is 
based on ratio spectra derivative and method B uses integrated area under curve, methanol is 
used as solvent for both the methods. The amplitudes at 280.01 nm and 286.12 nm of the first 
derivative of ratio spectra were selected to determine ATV and RTV, respectively by ratio 
derivative method and wavelength ranges of 246.97-252.03 nm and 240.78-244.16 nm were 
selected to determine ATV and RTV by AUC method in combined formulation. Beer’s law is 
obeyed in the concentration range of 15-75 µg/ mL and 5-25 µg/ mL for Atazanavir and 
Ritonavir, respectively by both the methods. The % assay in commercial formulation was found 
to be in the range 98.81-100.8% for ATV and 98.91-101.2% for RTV by the proposed methods. 
The methods were validated with respect to linearity, precision and accuracy. Recovery was 
found in the range of 99.20-99.96% for ATV and          99.12-99.97% for RTV by ratio 
derivative method and 99.08-99.66% for ATV and 99.78-100.6% for RTV by AUC method. The 
methods developed are simple, economical, precise and accurate and can be used for routine 
quality control of analytes in combined tablets15.  
A validated RP HPLC method for the estimation of Atazanavir sulphate in capsule 
dosage form on Agilent TC C18 (2) 250 x 4.6 mm, 5 µm column using mobile phase 
composition of water: acetonitrile (20:80 V/V) pH adjusted to 3.0.Flow rate was maintained at 1 
ml/ min at an ambient temperature. Quantification was achieved with ultraviolet detection at 255 
nm. The retention time obtained for Atazanavir sulphate was at 3.7 min. The detector response 
was linear in the concentration range of 10 – 80 µg/ mL. This method has been validated and 
shown to be specific, sensitive, precise, linear, accurate, rugged, robust and fast. Hence, this 
method can be applied for routine quality control of Atazanavir sulphate in capsule dosage forms 
as well as in bulk drug16. 
A validated RP HPLC method for the estimation of atazanavir in capsule dosage form on 
YMC ODS 150 × 4.6 mm, 5 µm column using mobile phase composition of ammonium 
dihydrogen phosphate buffer (pH 2.5) with acetonitrile (55:45 V/V). Flow rate was maintained at 
1.5 mL/ min with 288 nm UV detection. The retention time obtained for atazanavir was at 4.7 
min. The detector response was linear in the concentration range of 30 - 600 µg/ mL. This 
method has been validated and shown to be specific, sensitive, precise, linear, accurate, rugged, 
robust and fast. Hence, this method can be applied for routine quality control of atazanavir in 
capsule dosage forms as well as in bulk drug17. 
 To simple, sensitive, rapid spectrophotometric methods have been developed for 
simultaneous estimation of Atazanavir Sulfate (ATV) and Ritonavir (RTV) in tablets. First 
method involves solving simultaneous equations based on measurement of absorbance at two 
wavelengths 249.5 nm and 238.5 nm λ max of ATV and RTV, respectively. Second method is 
based on area under curve (AUC) and the wavelength ranges selected for analysis were 254.5-
244.5 nm for Atazanavir Sulfate and 243.5-233.5 nm for Ritonavir. Beer’s law was obeyed in the 
concentration range of           10-50 µg/ mL and 10-50 µg/ mL for ATV and RTV, respectively. 
The methods were validated as per ICH guidelines. Statistical analysis proved that the methods 
were accurate, precise, and reproducible for analysis of ATV and RTV in tablets. The wide 
linearity range, sensitivity, accuracy and simple procedure imply that the proposed technique 
demonstrated to be appropriate for routine analysis and quality control assay of tablets18.  
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                     AIM & OBJECTIVES 
 
3. AIM AND OBJECTIVES 
The drug analysis plays an important role in the development of drugs, their manufacture 
and the therapeutic use. Pharmaceutical industries rely upon quantitative chemical analysis to 
ensure that the raw materials used and the final product obtained meets the required 
specification. These drugs or formulation may be either in the new entities in the market or 
partial structural modification of the existing drugs or novel dosage forms or multi component 
dosage forms. The multi component dosage form proves to be effective due to the combined 
mode of action on the body. The complexity of dosage forms including the presence of multiple 
drug entities possesses considerable challenge to the analytical chemist during the development 
of assay procedure. 
The extensive literature survey carried out and revealed that very few methods are 
reported for the simultaneous estimation of these drugs in other combinations. Hence an attempt 
was made to develop a specific, precise, accurate, linear, simple, rapid, validated and cost 
effective HPLC method for the simultaneous estimation of Atazanavir sulphate and Ritonavir in 
combined dosage forms. 
The specific aim of the research was 
 To develop a method for the simultaneous estimation of Atazanavir sulphate and Ritonavir in 
bulk and Pharmaceutical dosage form and validate the proposed methods in accordance with 
ICH guidelines for the intended analytical application. 
 To validate the developed RP-HPLC method by using various validation parameters such as 
linearity, accuracy, system suitability, precision, robustness, ruggedness, limit of detection and 
limit of quantization. 
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4.  DRUG PROFILE 
Atazanavir sulphate  
Structure: 
 
IUPAC Name:(3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8hydroxy-4,11-dioxo-9-
(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-,5,6,10,13pentaazatetradecanedioic acid 
dimethyl ester, Sulphate 19,20. 
Molecular Formula: C38H52N6O7•H2SO4 
Molecular Weight : 802.93 
Category: Atazanavir sulphate is an antiretroviral drug of the protease inhibitor class. Like other 
antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). 
Description :A white to pale yellow crystalline powder. 
Solubility :It is soluble in methanol,ethanol,isopropanol and practically insoluble in water. 
Melting point :195-209oC 
pKa value: strongest acidic-11.92, strongest basic-4.42. 
Pharmacodynamics: 
Atazanavir sulphate is an azapeptide HIV-1 protease inhibitor (PI) with activity against 
Human Immunodeficiency Virus Type 1. HIV-1 protease is an enzyme required for the 
proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins 
found in infectious HIV-1. Atazanavir sulphate binds to the protease active site and inhibits the 
activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the 
formation of immature non-infectious viral particles. Protease inhibitors are almost always used 
in combination with at least two other anti-HIV drugs. Atazanavir sulphate is pharmacologically 
related but structurally different from other protease inhibitors and other currently available 
antiretrovirals. 
Mechanism of Action: 
Atazanavir sulphate selectively inhibits the virus-specific processing of viral Gag and 
Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, 
thus preventing the formation of mature virions. Atazanavir sulphate is not active against HIV-2. 
Pharmacokinetics: 
Absorption-Atazanavir is rapidly absorbed with a tmax of approximately 2.5 hours. 
Administration of Atazanavir sulphate with food enhances bioavailability and reduces 
pharmacokinetic variability. Oral bioavailability is 60-68%. 
Protein binding- 86%  
Route of elimination- Atazanavir sulphate dose was excreted urine. 
Metabolism- Metabolisedto Atazanavir sulphate by liver. 
Half life- 6.5 hours 
Adverse Reaction: 
Protease inhibitors commonly cause paresthesias, nausea, vomiting, and diarrhea 
disturbances in glucose and lipid metabolism also occur, including diabetes, 
hypertriglyceridemia, and hypercholesterolemia. 
Dose : Reyataz, latazanavir,zrivada 400 mg tablets.  
 
 
 
 
 
Ritonavir 
Structure: 
IUPAC NAME:1,3-thiazol
{[methyl({[2-(propan-2-yl)-1,3-thiazol
butanamido]-1,6-diphenylhexan-
Molecular Formula: C37H48N6O
Molecular Weight : 720.95 
Categories: Ritonavir is an antiretroviral drug of the protease inhibitor class. Like other 
antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV).
Description: White-to-off white powder.
Solubility: Freely soluble in methanol and in ethanol (95%) soluble in 2
Melting point: 120-123 °C 
pKa value: strongest acidic-13.68, strongest basic
Pharmacodynamics: 
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus 
Type 1. Protease inhibitors block the part of HIV called protease. HIV
required for the proteolytic cleavage of the viral polyprotein precursors in
functional proteins found in infectious HIV
 
 
-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)
-4-yl]methyl})carbamoyl]amino}      
2-yl]carbamate21,22. 
5S2 
 
-propanol.
-2.84. 
-1 protease is an enzyme 
to the individual 
-1. Ritonavir binds to the protease active site and 
-3-methyl-2-
 
 
inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins 
resulting in the formation of immature non-infectious viral particles. Protease inhibitors are 
almost always used in combination with at least two other anti-HIV drugs. 
Mechanism of action: 
Ritonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-
pol polyprotein, resulting in noninfectious, immature viral particles. 
Pharmacokinetics: 
Absorption-The absolute bioavailability of ritonavir has not been determined. 
Metabolism- Hepatic. 
Protein binding- 98-99%  
Route of elimination-Ritonavir dose was excreted urine. 
Metabolism- Metabolised to Ritonavir by liver. 
Half-life- 3 to 5 hours. 
Adverse Reactions /Side Effects: 
Protease inhibitors commonly cause paresthesias, nausea, vomiting, and diarrhea 
disturbances in glucose and lipid metabolism also occur, including diabetes, 
hypertriglyceridemia, and hypercholesterolemia. 
Dose: Norvir sofgel, Norvir100 mg tablets. 
 
 
 
 Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
     EXPERIMENTAL WORK 
 
5. EXPERIMENTAL WORK 
5.1 MATERIALS AND METHODS 
Equipments used:  
S.No Name Make 
1 Weighing Balance SHIMADZU 
2 pH meter ELCHEM 
3 Sonicator SAISONIC 
4 HPLC SHIMADZU LC-2010 with UV DETECTOR 
5 UV-Visible Spectroscopy PERKIN ELMER with LAMDA25 
 
Chemicals used: 
S.No Name Make 
1 Phosphate buffer HPLC  grade (MERCK) 
2 Acetonitrile HPLC  grade (MERCK) 
3 Methanol HPLC  grade (MERCK) 
4 Orthophosphoric acid HPLC  grade (RANCHEM) 
5 Purified water HPLC  grade (MILLI-Q) 
Active pharmaceutical Ingredient (pure drug) 
S.No Name Specification 
1 Atazanavir sulphate and Ritonavir  Reference  Standard 
 
 Marketed Formulation 
S.No Name                                                                      Manufacturer 
1 Atazotec Tablets Sai Mirra Innopharm 
 
SOLUBILITY 
Solubility of drug was observed by dissolving it in different solvents and it was found 
that drug having good solubility in followings. 
Solubility of drugs in different solvents 
5.2 METHOD DEVELOPMENT 
Determination of LAMBDA Max of Atazanavir sulphate by UV-Visible spectrophotometry 
Selection of wavelength: 
            Accurately Weighed and transferred Atazanavir sulphate equivalent to 25 mg into 50 mL 
clean, dry, volumetric flask, 50 mL of methanol was added, sonicated for 5 minutes, and filtered 
through 0.45 µm nylon membrane filter. Pipetted out 5 mL of the above solution, and diluted 
with 50 mL of methanol in 50 mL volumetric flask, and scanned between 200 to 400 by UV 
spectroscopy23. Shown in Figure-1. 
 
SOLVENT 
SOLUBILITY 
Atazanavir sulphate and Ritonavir 
Water - 
Acetonitrile + 
Methanol + 
0.1N NaoH - 
Determination of LAMBDA Max of Ritonavir by UV-Visible spectrophotometry 
Sample Preparation 
Accurately Weighed and transferred Ritonavir equivalent to 25 mg into 50 mL clean, dry, 
volumetric flask, 50 mL of methanol was added, sonicated for 5 minutes, and filtered through 
0.45 µm nylon membrane filter. Pipetted out 5 mL of the above solution, and diluted with 50 mL 
of methanol in 50 mL volumetric flask, and scanned between 200 to 400 by UV spectroscopy. 
Shown in Figure-2.  
Determination of ISOBESTIC point of Atazanavir sulphate and Ritonavir by UV-Visible 
spectrophotometry 
Sample Preparation 
Accurately Weighed and transferred  Atazanavir sulphate and Ritonavir equivalent to 25 
mg and 25 mg into 50 mL clean dry volumetric flask, 50 mL of methanol was added, sonicated 
for 5 minutes, and filtered through 0.45 µm nylon membrane filter. Pipette out both 5 mL of each 
solutions transferred into 50 mL volumetric flask, and diluted to 50 mL with methanol in 50 mL 
volumetric flask, and scanned between 200 to 400 by UV spectroscopy. Shown in Figure-3. 
Selection of mobile phase: 
The method development and validation of Atazanavir sulphate and Ritonavir requires 
greater resolution. Hence different solvent systems were tried. 
The trails are using SHIMADZU LC 2010 equipment with UV detector and isocratic 
pump. The system controlled by LC solution software. 
Selection of flow rate: 
            The flow rate of Atazanavir sulphate and Ritonavir were tried from 0.8 mL to 1.5 mL. 
 
 
 
Trial-1 
Buffer preparation: 
About 6.8 g of potassium dihydrogen orthophosphate was dissolved in      1000 mL of 
HPLC grade water and pH 3.0 was adjusted with orthophosphoric acid. It was filtered through 
0.45 µm nylon membrane filter and degassed with sonicator. It was used as a diluent for the 
preparation of sample and standard solution. 
Preparation of mobile phase: 
 Mobile phase consist of acetonitrile: methanol: buffer of pH 3.0 (65:5:30) was taken 
sonicated degas for 10 min and filtered through 0.45 µm nylon membrane filter. 
Standard Preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively. The chromatogram was shown in Figure-4. 
Chromatographic conditions: 
Column   :           Nucleodur C8 column(100 mm x 1.8 mm x5µm) 
Mobile phase :  Acetonitrile: Methanol: buffer pH 3.0 (65:5:30) 
Diluent :  HPLC grade methanol 
Flow rate   :  0.8 mL/ min 
Detector wavelength  :  210 nm 
Injection mode  :  Auto injector (vial) 
Injection volume  :  20 µl  
Trial-2 
Buffer preparation: 
About 6.8 g of potassium dihydrogen orthophosphate was dissolved in      1000 mL of 
HPLC grade water and pH 3.0 was adjusted with orthophosphoric acid. It was filtered through 
0.45 µm nylon membrane filter and degassed with sonicator. It was used as a diluent for the 
preparation of sample and standard solution. 
Preparation of mobile phase: 
 Mobile phase consist of acetonitrile: methanol: buffer of pH 3.0 (25:5:70) was taken 
sonicated degas for 10 min and filtered through 0.45 µm nylon membrane filter. 
 
Standard Preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively. The chromatogram was shown in Figure-5. 
Chromatographic conditions: 
Column   :          Nucleodur C8 column (100 mm x 1.8 mm x 5µm) 
Mobile phase :          Acetonitrile: Methanol: buffer pH 3.0 (25:5:70) 
Diluent                                    :  HPLC grade methanol 
Flow rate   :         0.9 mL/ min 
Detector wavelength  :         210 nm 
Injection mode             :        Auto injector (vial) 
Injection volume  :         20 µl  
 
Trial-3 
Buffer preparation: 
About 6.8 g of potassium dihydrogen orthophosphate was dissolved in      1000 mL of 
HPLC grade water and pH 3.0 was adjusted with orthophosphoric acid. It was filtered through 
0.45 µm nylon membrane filter and degassed with sonicator. It was used as a diluent for the 
preparation of sample and standard solution. 
Preparation of mobile phase: 
 Mobile phase consist of acetonitrile: methanol: buffer of pH 3.0 (60:10:30) was taken 
sonicated degas for 10 min and filtered through 0.45 µm nylon membrane filter. 
Standard Preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively. The chromatogram was shown in Figure-6. 
Chromatographic conditions: 
Column   :          Nucleodur C18 column(150 mm x 4.6 mm x5µm) 
Mobile phase :          Acetonitrile: Methanol: buffer pH 3.0 (60:10:30) 
Diluent :        HPLC grade methanol 
Flow rate   :        1.0 mL/ min 
Detector wavelength  :        210 nm 
Injection mode            :        Auto injector (vial) 
Injection volume  :        20 µl  
 
Trial-4 
Buffer preparation: 
About 6.8 g of potassium dihydrogen orthophosphate was dissolved in      1000 mL of 
HPLC grade water and pH 3.0 was adjusted with orthophosphoric acid. It was filtered through 
0.45 µm nylon membrane filter and degassed with sonicator. It was used as a diluent for the 
preparation of sample and standard solution. 
Preparation of mobile phase: 
 Mobile phase consist of acetonitrile: methanol: buffer of pH 3.0 (50:10:40) was taken 
sonicated degas for 10 min and filtered through 0.45 µm nylon membrane filter. 
Standard Preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively. The chromatogram was shown in Figure-7. 
Chromatographic conditions: 
Column   :          Nucleodur C18 column(150 mm x 4.6 mm x5µm) 
Mobile phase :          Acetonitrile: Methanol: buffer pH 3.0 (50:10:40) 
Diluent :         HPLC grade methanol 
Flow rate   :         1.2 mL/ min 
Detector wavelength  :         210 nm 
Injection mode            :        Auto injector (vial) 
Injection volume  :         20 µl  
 
OPTIMIZED METHOD: 
Buffer preparation: 
About 6.8 g of potassium dihydrogen orthophosphate was dissolved in      1000 mL of 
HPLC grade water and pH 3.0 was adjusted with orthophosphoric acid. It was filtered through 
0.45 µm nylon membrane filter and degassed with sonicator. It was used as a diluent for the 
preparation of sample and standard solution. 
Preparation of mobile phase: 
 Mobile phase consist of acetonitrile: methanol: buffer of pH 3.0 (44:11:45) was taken 
sonicated degas for 10 min and filtered through 0.45 µm nylon membrane filter. 
Standard Preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively. The chromatogram was shown in Figure-8. 
Chromatographic conditions: 
Column   :         Nucleodur C18 column(150 mm x 4.6 mm x5µm) 
Mobile phase :         Acetonitrile: Methanol: buffer pH 3.0 (44:11:45) 
Diluent :        HPLC grade methanol 
Flow rate   :        1.5 mL/ min 
Detector wavelength  :        210 nm 
Injection mode            :        Auto injector (vial) 
Injection volume  :        20 µl  
 
5.2.1 ASSAY OF ATAZANAVIR SULPHATE AND RITONAVIR: 
Standard preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively. The results were tabulated in Table-6 & the chromatogram 
was shown in Figure-9. 
Sample preparation: 
Weigh and powder 20 tablets and weigh powder equivalent to 218 mg of the sample was 
taken and 70 mL diluent. Sonicate for 30 minutes and make up to volume with the methanol. 
Filter Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with 
the mobile phase. With optimized Chromatographic condition a steady base line was recorded 
with mobile phase 20 µl quantity of sample solution was injected and the Chromatogram was 
recorded. The results was tabulated in Table-7 & the chromatogram is shown in Figure-10 
Procedure: 
Inject 20 µl of the standard, sample into the chromatographic system and measure the areas for 
the Atazanavir sulphate and Ritonavir peaks. 
Amount of drug in tablet was calculated using following formula 
Amount present:                                    
                            Sample area X standard weight  
                                                                                X dilution factor   X average weight 
                            Standard area X sample weight 
Percentage purity: 
                            Amount present / label claim X 100 
5.3 METHOD VALIDATION 
The chromatographic conditions were validated by evaluating linearity, accuracy, method 
precision, limit of detection (LOD), limit of quantitation (LOQ), ruggedness and robustness in 
accordance with ICH guidelines24.  
5.3.1 SPECIFICITY: 
 Specificity is the ability to measure accurately and specifically the analyte of interest in the 
presence of other components that may be expected to be present in the sample matrix. It is a 
measure of the degree of interference from such things as other active ingredients, excipients, 
impurities, and degradation products, ensuring that a peak response is due to only to a single 
component; that is, that no co-elution exists. Specificity is measured and documented in a 
separation by the resolution, plate count, and tailing factor.  
Preparation of solutions: 
a) Placebo interference: 
Sample was prepared by taking the placebo equivalent to about the weight in portion of 
test preparation as per the test method and injected into the HPLC system. The chromatogram 
was shown in Figure-11. 
Acceptance criteria: 
Chromatogram of placebo should not show any peak at the retention time of analyte 
peak. 
b) Blank Interference  
Mobile phase was prepared as per the test method and injected and into the HPLC 
system. The chromatogram was shown in Figure-12. 
Acceptance criteria: 
Chromatogram of blank should not show any peak at the retention time of analyte peak. 
 
Standard preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively. The chromatogram was shown in Figure-13-14. 
5.3.2 SYSTEM SUITABILITY: 
System Suitability was the checking of a system to ensure system performance before or 
during the analysis of unknowns. Parameters such as plate count, tailing factor, resolution, and 
reproducibility are determined and compared against the specification set for the method. These 
parameters are measured during the analysis of a system suitability sample that is a mixture of 
main components and expected by-product. The results was tabulated in Table-8   
5.3.3 LINEARITY AND RANGE: 
Preparation of stock solution: 
         Weigh accurately 68 mg of Atazanavir sulphate Standard and 20 mg of Ritonavir Standard 
into a 100 mL volumetric flask, dissolve and make up the volume with methanol. The solution 
contains 680 µg/ mL and 200 µg/ mL concentration of Atazanavir sulphate and Ritonavir 
respectively.  
Preparation of linearity solution (50%): 
         2.5 mL of stock solution was taken in 50 mL of volumetric flask dilute up to the mark with 
diluent. The solution contains 34 µg/ mL and 10 µg/ mL concentration of Atazanavir sulphate 
and Ritonavir respectively.   
Preparation of linearity solution (80%): 
         4.0 mL of stock solution was taken in 50 mL of volumetric flask dilute up to the mark with 
diluent.The solution contains 54 µg/ mL and 16 µg/ mL concentration of Atazanavir sulphate 
and Ritonavir respectively.   
Preparation of linearity solution (100%): 
         5.0 mL of stock solution was taken in 50 mL of volumetric flask dilute up to the mark with 
diluent. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir sulphate 
and Ritonavir respectively.    
Preparation of linearity solution (120%): 
         6.0 mL of stock solution was taken in 50 mL of volumetric flask dilute up to the mark with 
diluent. The solution contains 82 µg/ mL and 24 µg/ mL concentration of Atazanavir sulphate 
and Ritonavir respectively.    
Preparation of linearity solution (150%): 
         7.5 mL of stock solution was taken in 50 mL of volumetric flask dilute up to the mark with 
diluent. The solution contains 102 µg/ mL and 30 µg/ mL concentration of Atazanavir sulphate 
and Ritonavir respectively.    
Procedure: 
Each level of the above solutions was injected into the chromatographic system for five 
replicate and the peak area was measured. A graph was plotted (peak area versus concentration) 
and the correlation coefficient (r2) was calculated. The results were tabulated in Table 9 & the 
chromatograms were shown in Figure 15-21. 
5.3.4 PRECISION: 
         Precision was the measure of the degree of repeatability of an analytical method under 
normal operation and it was normally expressed as the relative standard deviation for a 
statistically number of samples. Precision should be performed at three different levels: 
repeatability, intermediate precision and reproducibility. 
Standard preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively.  
Sample preparation: 
Weigh and powder 20 tablets and weigh powder equivalent to 218 mg of the sample was 
taken and 70 mL diluent. Sonicate for 30 minutes and make up to volume with the methanol. 
Filter Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with 
the mobile phase. The results were tabulated in Table 9 & the chromatograms were shown in 
Figure 22-27. 
Procedure: 
         Six replicate Sample solutions were prepared as per the test method and injected as per the 
test procedure. 
5.3.5 ACCURACY: 
Accuracy is the measure of exactness of an analytical method, or closeness of agreement 
between the measured value and the value that is accepted either as a conventional, true value or 
an accepted reference value. Accuracy is measured as the percentage of analyte recovered by 
assay, spiking samples in a blind study.  
Preparation of stock solution: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. The 
solution contains 680 µg/ mL and 200 µg/ mL concentration of Atazanavir sulphate and 
Ritonavir respectively.  
80% Sample preparation: 
From the above stock solution 4 mL containing of Atazanavir sulphate and Ritonavir was 
taken into a 50 mL volumetric flask and diluted up to the mark with diluent. The solution was 
sonicated for 15 min and filtered through 0.45 µm nylon membrane filter. The above solution 
were inject into the HPLC column same procedure was repeated for three replicate. The results 
are tabulated in Table 11-12 & the chromatograms were shown in Figure 28-30. 
100% Sample preparation: 
From the above stock solution 5 mL containing of Atazanavir sulphate and Ritonavir was 
taken into a 50 mL volumetric flask and diluted up to the mark with diluent. The solution was 
sonicated for 15 min and filtered through 0.45 µm nylon membrane filter. The above solution 
were inject into the HPLC column same procedure was repeated for three replicate. The results 
are tabulated in Table 11-12 & the chromatograms were shown in Figure 31-33. 
120% Sample preparation: 
         From the above stock solution 6 mL containing of Atazanavir sulphate and Ritonavir was 
taken into a 50 mL volumetric flask and diluted up to the mark with diluent. The solution was 
sonicated for 15 min and filtered through 0.45 µm nylon membrane filter. The above solution 
were inject into the HPLC column same procedure was repeated for three replicate. The results 
are tabulated in Table 11-12 & the chromatograms were shown in Figure 34-36. 
Procedure:  
   The standard solution was injected in triplicate for Accuracy -80%, Accuracy -100% and 
Accuracy -120% solutions.  
         Calculate the Amount found and Amount added for Atazanavir sulphate & Ritonavir and 
calculate the individual recovery and mean recovery values. 
                                     
          Sample peak area x weight of standard    
         % Recovery   =                                                                   X 100 
 Standard peak area x weight of sample 
 
 
5.3.6 INTERMEDIATE PRECISION (RUGGEDNESS): 
 Ruggedness is the degree of reproducibility of results obtained by the analysis of the same 
sample under a variety of normal test conditions i.e. different analysts, laboratories, instruments, 
reagents, assay temperatures, small variations in mobile phase, different days etc. (i.e. from 
laboratory to laboratory, from analyst to analyst). Acceptance criteria for ruggedness, the % RSD 
for the area of five standard injections should not be more than 2%. 
Standard preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively.  
Sample preparation: 
Weigh and powder 20 tablets and weigh powder equivalent to 218 mg of the sample was 
taken and 70 mL diluent. Sonicate for 30 minutes and make up to volume with the methanol. 
Filter Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with 
the mobile phase. The results are tabulated in         Table 13-14 & the chromatograms were 
shown in Figure 37-48. 
5.3.7 ROBUSTNESS: 
 As part of the robustness, deliberate change in the flow rate and mobile phase 
composition was made to evaluate the impact on the method. The mixed standard solution is 
injected in two replicate and % RSD was calculated. 
Standard preparation: 
Weigh accurately 68 mg of Standard Atazanavir sulphate and 20 mg of Standard 
Ritonavir into a 100 mL volumetric flask, dissolve and make up the volume with methanol. 
Transfer 5 mL of the solution into a 50 mL volumetric flask and make up the volume with the 
mobile phase. The solution contains 68 µg/ mL and 20 µg/ mL concentration of Atazanavir 
sulphate and Ritonavir respectively. The results are tabulated in Table 15-18 & the 
chromatograms were shown in Figure 49-60.  
5.3.8 LIMIT OF DETECTION: 
 The limit of detection (LOD) is defined as the lowest concentration of the analyte in a 
sample that can be detected, though not necessarily quantitated. It was a limit test that specifies 
whether or not an analyte is above or below a certain value. It was expressed in a concentration 
at a specified signal-to-noise ratio, usually a           2- or 3-to-1 ratio. The results were tabulated 
in Table 19 & the chromatogram was shown in Figure-61.             
LOD= 3.3 * σ / slope 
 
5.3.9 LIMIT OF QUANTITATION 
The limit of Quantification (LOD) defined as the lowest concentration of an analyte in a 
sample that can be determined with acceptable precision and accuracy under the stated 
operational conditions of the method. The chromatogram was shown in Figure-62. 
     LOD= 10 * σ / slope 
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 6. RESULTS AND DISCUSSION 
6.1 METHOD DEVELOPMENT: 
 
6.1.1 Selection of wavelength: 
               
λ Max of Atazanavir sulphate by UV-Visible spectrophotometry 
 
 
 
 
Fig. 1: λ max for Atazanavir sulphate:  249 nm 
Observation: 
It was concluded that Atazanavir sulphate shows maximum absorbance at    249 nm. 
 λ Max of Ritonavir by UV-Visible spectrophotometry 
 
 
 
 
 
Fig. 2: λ max for Ritonavir: 239 nm 
 
Observation: 
It was concluded that Ritonavir shows maximum absorbance at 239 nm. 
 
 
Isobestic point of Atazanavir sulphate and Ritonavir by UV-Visible spectrophotometry 
 
 
 
 
                             Fig. 3: Overlaid spectrum of Atazanavir sulphate and Ritonavir 
Observation: 
The overlaid spectrum of Atazanavir sulphate and Ritonavir shows maximum absorbance 
at 210 nm and was used for method development. 
6.1.2 DEVELOPMENT TRAILS: 
Selection of flow rate: 
The flow rate was changed from 0.8-1.5 mL/ min-1 and the chromatogram was developed. 
The drugs eluted with small differences in fronting and tailing except at 1.5 mL/ min-1 and it was 
selected for analysis. 
Trial-1 
Table 1: Chromatographic condition  
Parameters Description 
Column Nucleodur C8 column (100 mm x 1.8 mm x 5 µm) 
Mobile Phase Acetonitrile : Methanol: Phosphate buffer pH 3.0 (65:5:30) 
Diluent HPLC grade methanol 
Flow rate 0.8 mL min-1 
Wavelength 210 nm 
Injection mode Auto injector (vial) 
Injection volume  20 µL 
 
 
Fig. 4: Chromatogram of Atazanavir sulphate and Ritonavir 
Observation: 
           Both Atazanavir sulphate and Ritonavir was eluted but resolution was not properly. So the 
flow rate and mobile phase ratio has been changed for next trial. 
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Trial-2 
Table 2: Chromatographic condition 
 
 
Fig. 5: Chromatogram of Atazanavir sulphate and Ritonavir 
Observation:  
 The number of Theoretical plates for the Atazanavir sulphate and Ritonavir peaks is NLT 
2000. So the flow rate and column has been changed for next trial. 
Parameters Description 
Column Nucleodur C8column (100 mm x 1.8 mm x 5 µm) 
Mobile Phase Acetonitrile : Methanol: Phosphate buffer pH 3.0 (25:5:70) 
Diluent HPLC grade methanol 
Flow rate 0.9 mL min-1 
Wavelength 210 nm 
Injection mode Auto injector (vial) 
Injection volume  20 µL 
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Trial-3 
Table 3: Chromatographic condition  
Parameters Description 
Column Nucleodur C18column (150 mm x 4.6 mm x 5 µm) 
Mobile Phase Acetonitrile : Methanol: Phosphate buffer pH 3.0 (60:10:30) 
Diluent HPLC grade methanol 
Flow rate 1.0 mL min-1 
Wavelength 210 nm 
Injection mode Auto injector (vial) 
Injection volume  20 µL 
 
 
 
Fig. 6: Chromatogram of Atazanavir sulphate and Ritonavir 
 
Observation:  
Peak broading obtain at Ritonavir. So the mobile phase ratio and flow rate has been 
changed for next trial. 
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Trial-4 
Table 4: Chromatographic condition  
Parameters Description 
Column Nucleodur C18column (150 mm x 4.6 mm x 5 µm) 
Mobile Phase Acetonitrile : Methanol: Phosphate buffer pH 3.0 (50:10:40) 
Diluent HPLC grade methanol 
Flow rate 1.2 mL min-1 
Wavelength 210 nm 
Injection mode Auto injector (vial) 
Injection volume  20 µL 
 
 
 
Fig. 7: Chromatogram of Atazanavir sulphate and Ritonavir 
Observation: 
           Atazanavir sulphate was eluted properly but Ritonavir retention time greated. So the 
mobile phase ratio has been changed for next trial. 
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OPTIMIZED METHOD  
Table 5: Chromatographic condition 
Parameters Description 
Column Nucleodur C18column (150 mm x 4.6 mm x 5 µm) 
Mobile Phase Acetonitrile : Methanol: Phosphate buffer pH 3.0 (44:11:45) 
Diluent HPLC grade methanol 
Flow rate 1.5 mL min-1 
Wavelength 210 nm 
Injection mode Auto injector (vial) 
Injection volume  20 µL 
 
 
 
Fig. 8: Chromatogram of Atazanavir sulphate and Ritonavir 
Observation: 
            Resolution, theoretical plates and symmetric factor were found to be within the limit. So 
this method is finalized as the optimized method.   
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ASSAY: 
Table 6: Assay data for standard Atazanavir sulphate and Ritonavir 
 
 
 
 
 
 
 
 
Table 7: Assay data for tablets of Atazanavir sulphate and Ritonavir 
  
 
 
 
 
 
 
 
 
Fig. 9:  Standard chromatogram of Atazanavir sulphate and Ritonavir. 
 
S.No. 
Standard 
 Atazanavir sulphate  Ritonavir 
1 1970033 568671 
2 1974636 560152 
3 1945756 560190 
Avg 1963475 560181 
 
S.No. 
Standard 
 Atazanavir sulphate  Ritonavir 
1 1972526 555272 
2 1976472 555303 
3 1977694 553068 
Avg 1975564 554547 
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Fig. 10:  Chromatogram of marketed formulation of Atazanavir sulphate and Ritonavir 
Formula: 
Amount present:    Sample area X standard weight 
                                                                                  X dilution factor X average weight 
                                Standard area X sample weight  
Percentage purity: Amount present/label claim X 100 
For Atazanavir sulphate: 
                                 1975564 X 63.5 X 5 X 100 X 50 X 1025.5 
                            =   1963475 X 100 x 50 X 220.5 X 5 
                            = 297.10 mg 
Percentage purity: 
                            = 297.10/300 X 100 
                            = 99.05 % 
For Ritonavir: 
                                 554547 X 21.5 X 5 X 100 X 50                                                                                               
                            =                                                        X 1025.5 
                                 560181 X 100 x 50 X 220.1 X 5 
                            = 99.20 mg  
Percentage purity: 
                            = 99.20/100X 100 
                            = 99.20 % 
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6.2. METHOD VALIDATION 
6.2.1 SPECIFICITY: 
Specificity is the ability to assess unequivalently the analyte in the presence of components, 
which may be expected to be present. Typically these might include impurities, matrix, degradants 
etc.  It is evaluated by injecting the blank and the control sample solution prepared as per the 
proposed method to check for the interference if any peak at the retention time of Atazanavir 
sulphate and Ritonavir. 
The specificity of the HPLC method was complete separation of Atazanavir sulphate and 
Ritonavir was noticed in presence of tablet excipients. In addition there was no interference at the 
retention time of Atazanavir sulphate and Ritonavir in the chromatogram of placebo solution. 
Name of the solution Retention time in min 
Blank No peak 
Placebo No peak 
Standard  3.06 and 6.18 
Sample 3.13 and 6.10 
 
 
 
Fig. 11: Chromatogram of placebo solution 
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 Fig. 12: Chromatogram of blank solution 
 
Fig. 13: Chromatogram of standard of Atazanavir sulphate and Ritonavir 
 
Fig. 14: Chromatogram of marketed formulation of Atazanavir sulphate and Ritonavir 
Result: 
The method was found to be specific because it did not show any extra peaks and there is 
no interference from excipients.  
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6.2.2 SYSTEM SUITABILITY PARAMETERS: 
           The system is suitable for analysis if the relative standard deviation (RSD) of area counts 
in the six replicate injections for each peak should not be more than 2.0%. The USP plate count 
of peak should not be less than 2000 theoretical plates for HPLC. The tailing factor for each peak 
should not be more than 2.0 and the resolution for two peaks should not be less than 2.0. The 
results obtained indicate the good precision of the developed method. The system suitability 
parameters were presented in table  
Table 8: System Suitability Parameters 
S. No. Parameters Atazanavir sulphate Ritonavir 
1 Theoretical plates 6336 7379 
2 
3 
Symmetric factor 
Resolution 
1.05 
6.65 
1.04 
6.65 
4 Tailing factor 1.15 1.32 
Acceptance criteria:  
Theoretical plate’s ≥ 2000, symmetric factor ≤ 2, tailing factor ≤ 2. 
Result:  
From the above table it was concluded that result obtained was within the limit only. 
6.2.3 LINEARITY: 
Linearity is determined by calculating the regression line using a mathematical treatment of 
the results (i.e. least mean squares) vs. analyte concentration. The range of the method is the 
interval between the upper and lower levels of an analyte that have been determined with 
acceptable precision, accuracy and linearity. It is determined on either a linear or nonlinear 
response curve (i.e. where more than one range is involved) and is normally expressed in the 
same units as the test results. 
 
Table 9:  Linearity of Atazanavir sulphate and Ritonavir
S.No. 
Atazanavir
Conc. (µg mL
1 34 
2 54 
3 68 
4 82 
5 102 
Slope  
Y-Intercept  
Correlation 
coefficient 
 
 
 
 
Fig. 15: Calibration plot of 
 
 
Ritonavir
-1) Peak Area Conc. (µg mL-1) 
842922 10 
1310821 16 
1658694 20 
1996529 24 
2468854 30 
8221  
24201  
0.999  
Atazanavir sulphate 
 
Peak Area 
292661 
455824 
577054 
691459 
861146 
1471 
28693 
0.999 
 
Fig. 16: Calibration plot of 
Fig. 17: Chromatogram of 
Fig. 18: Chromatogram of 
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 Fig. 19: Chromatogram of Atazanavir sulphate and Ritonavir for Linearity-3 
 
Fig. 20: Chromatogram of Atazanavir sulphate and Ritonavir for Linearity-4 
 
Fig. 21: Chromatogram of Atazanavir sulphate and Ritonavir for Linearity-5 
Acceptance criteria:  
Correlation Coefficient should be not less than 0.9990 
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Result: 
The relationship between the concentration of Atazanavir sulphate and Ritonavir was 
linear in the specific range and the correlation coefficient was found to be within limit only. The 
correlation coefficient of Atazanavir sulphate and Ritonavir was found to be 0.999 and 0.999. 
6.2.4 PRECISION: 
The precision of an analytical method is the degree of agreement among individual test 
results obtained when the method is applied to multiple sampling of a homogenous sample. 
Precision is a measure of the reproducibility of the whole analytical method (including sampling, 
sample preparation and analysis) under normal operating circumstances. Precision is determined 
by using the method to assay a sample for a sufficient number of times to obtain statistically 
valid results. The precision is then expressed as the relative standard deviation. 
Table 10: Method precision:  
S.No 
ATAZANAVIR SULPHATE RITONAVIR 
Rt Peak area Rt Peak area 
1 3.10 1975564 6.03 534547 
2 3.10 1976472 6.08 535303 
3 3.11 1977694 6.09 533068 
4 3.11 1975450 6.09 531885 
5 3.10 1980537 6.08 550278 
6 3.13 1973346 6.10 545065 
Mean  1976511  538358 
SD  2435.14  7494.10 
%RSD  0.12  1.39 
 
 Fig. 22: Chromatogram of Atazanavir sulphate and Ritonavir for precision-1 
 
Fig. 23: Chromatogram of Atazanavir sulphate and Ritonavir for precision -2 
 
 
Fig. 24: Chromatogram of Atazanavir sulphate and Ritonavir for precision -3 
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 Fig. 25: Chromatogram of Atazanavir sulphate and Ritonavir for precision -4 
 
Fig. 26: Chromatogram of Atazanavir sulphate and Ritonavir for precision -5 
 
Fig. 27: Chromatogram of Atazanavir sulphate and Ritonavir for precision -6 
Acceptance Criteria:  
            % RSD of the sample replicate should not be more than 2.  
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Result: 
            The % RSD for Atazanavir sulphate and Ritonavir it was found to be 0.12 and 1.39 in 
AUC, respectively. The % RSD value indicates a good degree of precision within the specified 
range. 
6.2.5 ACCURACY:  
Accuracy is a measure of the closeness of test results obtained by a method to the true 
value. Accuracy indicates the deviation between the mean value found and the true value. It is 
determined by applying the method to samples to which known amounts of analyte have been 
added. These should be analyzed against standard and blank solutions to ensure that no 
interference exists. The accuracy is then calculated from the test results as a percentage of the 
analyte recovered by the assay. 
Table-11: Accuracy for Atazanavir Sulphate 
AMOUNT 
OF SPIKED Peak Area 
Amount of 
added 
(mg) 
Amount 
recovered 
(mg) 
% Recovery Average 
recovery 
% 
RSD 
80% 
1559712 240.59 240.31 99.88 
100.01 
 
0.17 
 
1566912 239.49 239.80 100.13 
1563075 239.69 240.48 100.33 
100% 
1986505 299.88 301.13 100.42 
100.40 
 
0.31 
 
1979715 299.29 299.53 100.08 
1986012 299.98 302.06 100.69 
120% 
2316272 361.70 360.71 99.73 
99.91 
 
0.24 
 
2317572 358.92 359.51 100.16 
2327359 362.01 361.38 99.83 
Table-12: Accuracy for Ritonavir 
AMOUNT OF 
SPIKED 
Peak 
Area 
Amount of 
added 
(mg) 
Amount 
recovered 
(mg) 
% Recovery Average 
recovery 
% 
RSD 
80% 
422000 79.51 79.51 100.00 
100.31 
 
0.27 
 
423557 78.88 79.27 100.49 
423937 79.41 79.76 100.43 
100% 
541035 100.04 100.29 100.25 
100.12 
 
0.61 
 
539736 100.23 99.86 99.63 
542332 100.38 100.87 100.49 
120% 
629877 120.49 119.95 99.55 
100.31 
 
0.29 
 
632736 119.46 120.03 100.48 
635575 119.61 120.68 100.89 
 
 
Fig. 28: Chromatogram of Atazanavir sulphate and Ritonavir for 80%spiking-1 
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 Fig. 29: Chromatogram of Atazanavir sulphate and Ritonavir for 80% spiking-2 
 
Fig. 30: Chromatogram of Atazanavir sulphate and Ritonavir for 80%spiking-3 
 
Fig. 31: Chromatogram of Atazanavir sulphate and Ritonavir for 100% spiking-1 
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 Fig. 32: Chromatogram of Atazanavir sulphate and Ritonavir for 100% spiking-2 
 
Fig. 33: Chromatogram of Atazanavir sulphate and Ritonavir for 100% spiking-3 
 
Fig. 34: Chromatogram of Atazanavir sulphate and Ritonavir for 120% spiking-1 
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 Fig. 35: Chromatogram of Atazanavir sulphate and Ritonavir for 120% spiking-2 
 
Fig. 36: Chromatogram of Atazanavir sulphate and Ritonavir for 120% spiking-3 
Acceptance criteria: 
           The mean percentage recovery of the Atazanavir sulphate and Ritonavir at each spike 
level should be not less than 98.0% and not more than 102.0%. 
Result: 
From the Accuracy table it was found that % Recovery of the drug was found to be in the 
range of 99.91-100.40 % and 100.12-100.31 % for Atazanavir sulphate and Ritonavir 
respectively. This indicates that the method was accurate.  
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6.2.6 RUGGEDNESS: 
            Ruggedness is the degree of reproducibility of results obtained by the analysis of the same 
sample under a variety of normal test conditions i.e. different analysts, laboratories, instruments, 
reagents, assay temperatures, small variations in mobile phase, different days etc. (i.e. from 
laboratory to laboratory, from analyst to analyst). Acceptance criteria for ruggedness, the % RSD 
for the area of five standard injections should not be more than 2%.  
Table-13: Intraday Precision and Intermediate precision analyst-1 
 
Parameter 
 
Inj 
Atazanavir Sulphate Ritonavir 
Rt AUC %ASSAY Rt AUC %ASSAY 
Intraday 
Precision 
Data 
Analyst-1 
 
1 3.116 1987964 99.78 6.105 544358 100.42 
2 3.112 1986984 99.14 6.062 546722 100.26 
3 3.107 1979854 99.56 6.047 541098 100.00 
4 3.127 1985269 99.60 6.027 544037 100.32 
5 3.106 1985060 99.41 6.040 546826 100.65 
6 3.107 1998324 99.80 6.041 539046 98.94 
Mean   
1987242 
 
99.55 
 
 
543681 
 
100.10 % R.S.D  0.31 0.25  0.57 0.60 
 
Fig.37: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -1 
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 Fig. 38: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -2 
 
Fig. 39: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -3 
 
Fig. 40: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -4 
 
 
0.0 2.5 5.0 7.5 min 
0 
250 
500 
mV 
 
3.
12
7 
6.
02
7 
0.0 2.5 5.0 7.5 min 
0 
250 
500 
mV 
 
3.
10
7 
6.
04
7 
0.0 2.5 5.0 7.5 min 
0 
250 
500 
mV 
 
3.
11
2 
6.
06
2 
 Fig. 41: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -5 
 
Fig. 42: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -6 
Table-14: Intermediate precision analyst-2 
 
Parameter 
 
Inj 
Atazanavir Sulphate Ritonavir 
Rt AUC %ASSAY Rt AUC %ASSAY 
Intraday 
Precision 
Data 
Analyst-2 
 
1 3.015 1993291 100.05 6.125 542741 100.12 
2 3.012 1988365 99.21 6.121 543104 99.60 
3 3.112 1986281 99.88 6.101 549121 101.49 
4 3.001 1996202 100.15 6.031 547160 100.89 
5 3.006 1974107 98.86 6.141 545397 100.38 
6 3.017 1997980 99.78 6.121 547218 100.44 
Mean       
% R.S.D  0.44 0.51  0.46 0.64 
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 Fig.43: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -1 
 
Fig. 44: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -2 
 
Fig. 45: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -3 
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 Fig. 46: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -4 
 
Fig. 47: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -5 
 
Fig. 48: Chromatogram of Atazanavir sulphate and Ritonavir for ruggedness -6 
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Result: 
Individual % RSD of Assay was found to be 0.25 % and 0.60 %.  The Relative standard 
deviation of % Assay of Analyst 1 found to be for Atazanavir sulphate 0.31 % and Ritonavir 
0.57 % and the sample passed the test. The relative standard deviation of % Assay of Analyst 2 
found to be for Atazanavir sulphate 0.44 % and Ritonavir 0.46 % respectively.   
6.2.7 ROBUSTNESS: 
The robustness of an analytical procedure is a measure of its capacity to remain 
unaffected by a small, but deliberate variation in the method parameters and provides an 
indication of its reliability during normal usage. Robustness of the method was investigated 
under a variety of conditions including deliberate changes in the temperature, mobile phase 
composition and change in flow rate. The degree of reproducibility of the results obtained as a 
result of small variations in the method parameters has proven that the method is robust. The 
relative standard deviation for the assay value of Atazanavir sulphate and Ritonavir obtained under 
deliberately modified chromatographic conditions should be less than 2%. The results obtained 
in the present study also indicate the method is robust.  
Change in flow rate: ± 0.1 
Table 15: Flow rate changes for Atazanavir Sulphate 
S.NO 
FLOW RATE 1.2mL/min FLOW RATE 1.3mL/min 
FLOW RATE 
1.4mL/min 
Rt Peak area Rt Peak area Rt Peak area 
1 3.12 1995819 3.13 1991097 3.21 1993678 
2 3.10 1972906 3.12 1999055 3.24 1990321 
Mean  1984363  1995076  1992000 
SD  16201.9  5627.1  2373.8 
% RSD  0.81  0.28  0.12 
 
 
Table 16: Flow rate changes for Ritonavir 
S.NO 
FLOW RATE 1.2mL/min FLOW RATE 1.3mL/min 
FLOW RATE 
1.4mL/min 
Rt Peak area Rt Peak area Rt Peak area 
1 6.13 542654 6.14 559592 6.23 551280 
2 6.13 543459 6.13 556273 6.24 550695 
Mean  543056  559432  550988 
SD  569.2  225.5  413.7 
% RSD  0.10  0.04  0.07 
 
 
Fig. 49: Flow rate changes (Flow rate 1.2mL)   
 
Fig. 50: Flow rate changes (Flow rate 1.2mL)   
 
0.0 2.5 5.0 7.5 min 
0 
25 
50 
75 
mV 
 
3.
10
3 
6.
13
1 
0.0 2.5 5.0 7.5 min 
0 
25 
50 
75 
mV 
 
3.
12
3 
6.
13
0 
 Fig. 51: Flow rate changes (Flow rate 1.3mL)   
 
Fig. 52: Flow rate changes (Flow rate 1.3mL)   
 
Fig. 53: Flow rate changes (Flow rate 1.4mL)   
 
 
0.0 2.5 5.0 7.5 min 
0 
25 
50 
75 
mV 
 
3.
21
3 
6.
23
3 
0.0 2.5 5.0 7.5 min 
0 
25 
50 
75 
mV 
 
3.
12
3 
6.
13
4 
0.0 2.5 5.0 7.5 min 
0 
25 
50 
75 
mV 
 
3.
13
3 
6.
14
5 
 Fig. 54: Flow rate changes (Flow rate 1.4mL)   
Table 17: Mobile phase ratio changes for Atazanavir Sulphate 
S.NO 
MOBILE PHASE   
50:10:40 
MOBILE PHASE 
CONSTANT    
44:11:45 
MOBILE PHASE  
45:15:40 
Rt Peak area Rt Peak area Rt Peak area 
1 3.13 1982858 3.10 1979925 3.13 1984227 
2 3.14 1983273 3.11 1983419 3.11 1983419 
Mean  1983066  1981672  1983823 
SD  293.45  2470.63  571.34 
% RSD  0.01  0.12  0.03 
 
 
 
 
 
 
0.0 2.5 5.0 7.5 min 
0 
25 
50 
75 
mV 
 
3.
24
5 
6.
24
3 
Table 18: Mobile phase ratio changes for Ritonavir 
S.NO 
MOBILE PHASE   
50:10:40 
MOBILE PHASE 
CONSTANT    
44:11:45 
MOBILE PHASE  
45:15:40 
Rt Peak area Rt Peak area Rt Peak area 
1 6.15 549370 6.13 541350 6.14 543884 
2 6.18 542393 6.13 543884 6.13 549614 
Mean  545882  542617  546749 
SD  4933.48  1791.81  4051.72 
% RSD  0.90  0.33  0.74 
 
 
Fig. 55: Mobile phase ratio changes (ACN 50: Methanol 10: Buffer 40) 
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 Fig. 56: Mobile phase ratio changes (ACN 50: Methanol 10: Buffer 40) 
 
Fig. 57: Mobile phase ratio changes (ACN 44: Methanol 11: Buffer 45) 
 
 
Fig. 58: Mobile phase ratio changes (ACN 44: Methanol 11: Buffer 45) 
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 Fig. 59: Mobile phase ratio changes (ACN 45: Methanol 15: Buffer 40) 
 
Fig. 60: Mobile phase ratio changes (ACN 45: Methanol 15: Buffer 40) 
Result: 
When flow rate was altered RT has no changed significantly, when mobile phase was 
altered there was no change in the RT significantly. The method was found to be robust as per 
ICH Guidelines. 
6.2.8 LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTITATION (LOQ): 
LOD and LOQ were calculated by using instrumental method.  
 Limit of Detection for Atazanavir sulphate        = 0.0023µg mL-1 
 Limit of Quantitation for Atazanavir sulphate    = 0.0161µg mL-1 
 Limit of Detection for Ritonavir                         = 0.0006µg mL-1 
 Limit of Quantitation for Ritonavir                     = 0.0047µg mL-1 
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Table 19: Limit of Detection and Quantitation 
Contents Atazanavir Ritonavir 
LOD (S/N) 3.1 3.1 
LOQ (S/N) 9.9 10.1 
 
Fig. 61:  LOD chromatogram of Atazanavir sulphate and Ritonavir 
 
Fig. 62: LOQ chromatogram of Atazanavir sulphate and Ritonavir. 
Acceptance criteria: 
 LOD should not exceed LOQ. 
Result: 
LOD and LOQ of Atazanavir sulphate was found to be 0.0023 µg mL-1 and 0.016 µg mL-1 
LOD and LOQ of Ritonavir was found to be 0.0006 µg mL-1and 0.0047 µg mL-1. 
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  SUMMARY & CONCLUSIONS 
 
7.  SUMMARY AND CONCLUSIONS 
In the present study, new RP-HPLC method for simultaneous estimation of Atazanavir 
sulphate and Ritonavir in bulk and pharmaceutical dosage form was developed. The developed 
method was validated for various parameters such as accuracy, precision, ruggedness, 
linearity, robustness, system suitability, specificity, limit of detection and limit of quantification 
as per ICH guidelines.The results of the studies are summarized as follows 
A ) Method development: 
 Trial 5 was optimized for the method development of deliberately changing the 
chromatographic conditions. 
 Column used was C18 Nucleodur (150 mm X 4.6 mm X 5 µm), mobile phase 
composition of ACN: Methanol: phosphate buffer pH 3.0 was adjusted with 
orthophosphoric acid in the ratio (44:11:45 V/V/V). The Flow rate                       1.5 mL 
min-1 with UV detection was carried out at 210 nm. 
 Assay percentage was found to be 99.05 % for Atazanavir sulphate and            99.20 % 
for Ritonavir. 
B ) Validation Parameters: 
 The calibration was linear with correlation coefficient 0.999 for Atazanavir sulphate and 
0.999 for Ritonavir. 
 In precision it was found that % RSD is less than 2% which indicates that the  
proposed method has good reproducibility. 
 The system suitability parameter indicates good resolution of both the       peaks   > 2. 
 From the Accuracy was found that % Recovery of the drug was found to be in the range 
of 99.91-100.40 % and 100.12-100.31 % for Atazanavir sulphate and Ritonavir 
respectively. 
 Robustness, When flow rate was altered RT has no changed significantly, when mobile 
phase was altered there was no change in the RT significantly. 
 LOD and LOQ, the limit of detection (LOD) was 0.002 µg mL-1 for Atazanavir sulphate 
and 0.001 µg mL-1 for Ritonavir and the limit of quantitation (LOQ) was 0.016 µg mL-1 
for Atazanavir sulphate and 0.004 µg mL-1 for Ritonavir. 
Conclusions: 
The results of the present study indicated that the developed method is simple, precise 
and cost effective for the simultaneous estimation of Atazanavir sulphate and Ritonavir for 
routine quality control analysis of these either in bulk and pharmaceutical formulation. 
The developed and validated RP-HPLC method outlined is very obvious, affordable, 
dynamic, low cost, rapid easy to perform with small sample volume and good repeatability. It 
can be adopted for the routine quality control analysis of simultaneous determination of 
Atazanavir sulphate and Ritonavir because of good resolution of the chromatographic peaks.  
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9. APPENDIX 
% - Percentage. 
µg - Microgram 
µl   - Microlitre 
µm     - Micrometer 
ACN    - Acetonitrile 
AUC   - Area under curve 
cm   - Centimeter 
HPLC                   - High performance liquid chromatography 
HPTLC  - High performance thin layer chromatography 
LOD   - Limit of detection 
LOQ - Limit of Quantitation 
Mg - Milligram 
RP-HPLC             - Reverse phase high performance liquid 
chromatography 
ICH    - International conference of harmonization 
min   - Minute 
FDA - Food and drug administration 
WHO - World health organization 
USFDA     - United state food and drug administration 
NP-HPLC              - Normal phase high performance liquid 
chromatography 
mL    - Millilitre 
mm     - Millimetre 
nm   - Nanometer 
Avg wt - Average weight 
RSD - Relative standard deviation 
r2 - Regression coefficient 
ATA - Atazanavir Sulphate 
RIT - Ritonavir 
C18 - Carbon 18 
V/V                                 - Volume by volume 
 
